Learn More About CMT Research
Find a CMTA Center of Excellence
Get Involved with our Youth Program
Participate in a CMTA Event

CMTA News

CMT2F Natural History Study Nears Full Recruitment as Biomarker Analysis Begins

Read More

2024 CMTA Patient and Research Summit

Recap: 2024 CMTA Patient & Research Summit

Read More

CMTA’s CRISPR Research Initiative Advances for CMT1A and CMT1B

CMTA’s CRISPR Research Initiative Advances for CMT1A and CMT1B

Read More

Your Participation Matters: Join the CMT2S Research Study

Read More

CMTA's Strategic Investment Advances Research for CMTA1A and CMT1B

CMTA’s Strategic Investment Advances Research for CMT1A and CMT1B

Read More

CMTA Supports the Accelerating Kids’ Access to Care Act (H.R.4758 / S.2372)

Read More

CMT2F Natural History Study Nears Full Recruitment as Biomarker Analysis Begins

CMTA’s CRISPR Research Initiative Advances for CMT1A and CMT1B

Your Participation Matters: Join the CMT2S Research Study

CMTA’s Strategic Investment Advances Research for CMT1A and CMT1B

Advancing the Understanding of CMT2A and CMT2F: A Call to Beat CMT

Exploring New Therapeutic Pathways for CMT1B: UPR Activation

CMTA-STAR Alliance Partner Actio Biosciences Receives FDA Orphan Drug Designation and Rare Pediatric Disease Designation for Their Treatment in Development for CMT2C

CMTA Alliance Partner Applied Therapeutics Plans to Submit an NDA for CMT-SORD, a Potential First Approval for the Treatment of any type of CMT

What is CMT?

Living With CMT

CMT doesn’t have to stop you from doing the things you want to do. We have ...

Living with CMT

Researching the Cure

Over $23.5 million invested in STAR research driving our vision of a world without CMT ..

Our Research